Clinical Trial

A Vaccine (Ad5.F35-hGCC-PADRE) for the Treatment of Gastrointestinal Adenocarcinoma

Active, Not Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated August 22, 2025 (before its estimated March 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
This phase IIA trial investigates the side effects of Ad5.F35-hGCC-PADRE vaccine and to see how well it works in treating patients with gastrointestinal adenocarcinoma. Ad5.F35-hGCC-PADRE vaccine may help to train the patient's own immune system to identify and kill tumor cells and prevent it from coming back.
Protocol Amendment History 12 amendments
This ClinicalTrials.gov record has been amended 12 times since 2019-09-27; most recent amendment 2025-08-20.
Status change: Suspended → Active, Not Recruiting 2025-01-02
Status change: Recruiting → Suspended 2024-01-29
Status change: Not Yet Recruiting → Recruiting 2020-11-19
Trial Details
NCT Number NCT04111172
Lead Sponsor Thomas Jefferson University
Conditions Pancreatic Ductal Adenocarcinoma, Colorectal Adenocarcinoma, Gastric Adenocarcinoma, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage IIA Gastric Cancer AJCC v8, Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIB Gastric Cancer AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8 +30 more
Enrollment 48 participants
Start Date 2020-11-10
Primary Completion 2026-03-01 (estimated)
Study Completion 2027-03-01 (estimated)
Updated on ClinicalTrials.gov 2025-08-22